{"pmid":32361703,"title":"Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report.","text":["Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report.","During the COVID-19 pandemic, we had a 25 years old male case without any underlying disease or history of autoimmune disease in COVID-19 Clinic, Isfahan, Iran. He presented with arthralgia and weakness so we started COVID-19 therapeutic regimen. In his hospitalization, creatinine increases and abnormalities in random urine sediment was seen. Methylprednisolone and cyclophosphamide were prescribed due to suspected glomerulonephritis. After renal biopsy the diagnose was confirmed as crescentic proliferative glomerulonephritis. The patient also, underwent plasmapheresis and intravenous immunoglobulin injection. He was discharged healthy without development of new pulmonary symptoms despite immunosuppressive treatment.","Iran J Kidney Dis","Moeinzadeh, Firouzeh","Dezfouli, Majid","Naimi, Azar","Shahidi, Shahrzad","Moradi, Hazhir","32361703"],"abstract":["During the COVID-19 pandemic, we had a 25 years old male case without any underlying disease or history of autoimmune disease in COVID-19 Clinic, Isfahan, Iran. He presented with arthralgia and weakness so we started COVID-19 therapeutic regimen. In his hospitalization, creatinine increases and abnormalities in random urine sediment was seen. Methylprednisolone and cyclophosphamide were prescribed due to suspected glomerulonephritis. After renal biopsy the diagnose was confirmed as crescentic proliferative glomerulonephritis. The patient also, underwent plasmapheresis and intravenous immunoglobulin injection. He was discharged healthy without development of new pulmonary symptoms despite immunosuppressive treatment."],"journal":"Iran J Kidney Dis","authors":["Moeinzadeh, Firouzeh","Dezfouli, Majid","Naimi, Azar","Shahidi, Shahrzad","Moradi, Hazhir"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361703","source":"PubMed","week":"202019|May 04 - May 10","locations":["Isfahan","Iran"],"countries":["Iran, Islamic Republic of"],"countries_codes":["IRN|Iran, Islamic Republic of"],"e_drugs":["Creatinine","Cyclophosphamide","Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666138495570149379,"score":9.490897,"similar":[{"pmid":32378314,"title":"Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options.","text":["Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options.","The Coronavirus Disease 2019 (COVID-19) pandemic imposes special challenges to immunocompromised transplant patients. Given the paucity of proven data in treating COVID-19, management of these patients is difficult, rapidly evolving, and is mainly based on anecdotal experience. We report 2 cases of heart transplant (HT) recipients with COVID-19. The first is a 59-year-old female with HT in 2012 who presented on March 20, 2020 with fever, hypoxia and ground-glass opacities on chest x-ray. She quickly progressed to acute hypoxic respiratory failure and vasoplegic shock. Despite reduction in immunosuppression, and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavir/ritonavir and broad-spectrum antibiotics, she ultimately passed away from multiorgan failure. The second case is a 75-year-old man with HT in 2000 who presented on April 2, 2020 after curbside testing revealed positive COVID-19. Given a milder presentation compared to the first patient, antimetabolite was discontinued and only hydroxychloroquine was started. Due to lack of clinical improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoagulation were initiated. The patient clinically improved with decreasing oxygen requirements and was discharged home. These two cases highlight the wide range of different presentations of COVID-19 in HT recipients, and the rapidity with which the management of these patients is evolving.","Am J Transplant","Holzhauser, Luise","Lourenco, Laura","Sarswat, Nitasha","Kim, Gene","Chung, Bow","Nguyen, Ann B","32378314"],"abstract":["The Coronavirus Disease 2019 (COVID-19) pandemic imposes special challenges to immunocompromised transplant patients. Given the paucity of proven data in treating COVID-19, management of these patients is difficult, rapidly evolving, and is mainly based on anecdotal experience. We report 2 cases of heart transplant (HT) recipients with COVID-19. The first is a 59-year-old female with HT in 2012 who presented on March 20, 2020 with fever, hypoxia and ground-glass opacities on chest x-ray. She quickly progressed to acute hypoxic respiratory failure and vasoplegic shock. Despite reduction in immunosuppression, and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroquine, lopinavir/ritonavir and broad-spectrum antibiotics, she ultimately passed away from multiorgan failure. The second case is a 75-year-old man with HT in 2000 who presented on April 2, 2020 after curbside testing revealed positive COVID-19. Given a milder presentation compared to the first patient, antimetabolite was discontinued and only hydroxychloroquine was started. Due to lack of clinical improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoagulation were initiated. The patient clinically improved with decreasing oxygen requirements and was discharged home. These two cases highlight the wide range of different presentations of COVID-19 in HT recipients, and the rapidity with which the management of these patients is evolving."],"journal":"Am J Transplant","authors":["Holzhauser, Luise","Lourenco, Laura","Sarswat, Nitasha","Kim, Gene","Chung, Bow","Nguyen, Ann B"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378314","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15982","locations":["hypoxia","immunoglobulin","multiorgan"],"e_drugs":["Hydroxychloroquine","tocilizumab","Methylprednisolone","lopinavir-ritonavir drug combination"],"topics":["Case Report"],"weight":1,"_version_":1666262687558926336,"score":130.94484},{"pmid":32181990,"title":"Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.","text":["Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.","The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia.","Am J Transplant","Zhu, Lan","Xu, Xizhen","Ma, Ke","Yang, Junling","Guan, Hanxiong","Chen, Song","Chen, Zhishui","Chen, Gang","32181990"],"abstract":["The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia."],"journal":"Am J Transplant","authors":["Zhu, Lan","Xu, Xizhen","Ma, Ke","Yang, Junling","Guan, Hanxiong","Chen, Song","Chen, Zhishui","Chen, Gang"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181990","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1111/ajt.15869","keywords":["covid-19","coronavirus","immunosuppression","pneumonia","renal transplantation"],"e_drugs":["Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666138492545007617,"score":125.90157},{"pmid":32415905,"title":"Coronavirus disease 2019 in renal transplant recipients: report of two cases.","text":["Coronavirus disease 2019 in renal transplant recipients: report of two cases.","Coronavirus disease 2019 (COVID-19) has been a pandemic worldwide. The data about COVID-19 in renal transplant recipient is deficiency. Herein we report two COVID-19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low-dose methylprednisolone-based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID-19 in renal transplant recipients.","Transpl Infect Dis","Cheng, D R","Wen, J Q","Liu, Z Z","Lv, T F","Chen, J S","32415905"],"abstract":["Coronavirus disease 2019 (COVID-19) has been a pandemic worldwide. The data about COVID-19 in renal transplant recipient is deficiency. Herein we report two COVID-19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low-dose methylprednisolone-based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID-19 in renal transplant recipients."],"journal":"Transpl Infect Dis","authors":["Cheng, D R","Wen, J Q","Liu, Z Z","Lv, T F","Chen, J S"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415905","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/tid.13329","keywords":["covid-19","sars-cov-2","immunosuppressant","methylprednisolone","renal transplant recipient"],"e_drugs":["Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666991242670505984,"score":124.16975},{"pmid":32447505,"title":"Pediatric COVID-19-associated rhabdomyolysis: a case report.","text":["Pediatric COVID-19-associated rhabdomyolysis: a case report.","COVID-19 is the illness caused by infection with the novel coronavirus SARS-CoV-2. Although myalgia is common in adults, it has not been noted as a common symptom in children. There have been a few reported cases of COVID-19-associated rhabdomyolysis in adults. This case report describes a 16-year-old boy who presented with fever, myalgias, mild shortness of breath with exertion, and dark-colored urine. COVID-19 PCR was positive. His initial creatinine kinase (CK) level was 427,656 U/L. Serum creatinine was normal for age. He was treated with isotonic intravenous fluids containing sodium bicarbonate to maintain urine output of 100-200 mL/h and urine pH > 7.0. His serum creatinine remained normal throughout the hospital stay and he was discharged on hospital day 12 with a CK of 6526 U/L. To our knowledge, no pediatric cases of COVID-19-associated rhabdomyolysis have been previously reported. Adult cases of rhabdomyolysis have been reported and a few reports have noted patients with elevated CK levels without rhabdomyolysis. Given this pediatric case of COVID-19-associated rhabdomyolysis, pediatric clinicians should be aware of this complication and manage fluids appropriately in order to prevent acute kidney injury.","Pediatr Nephrol","Gefen, Ashley M","Palumbo, Nancy","Nathan, Suresh K","Singer, Pamela S","Castellanos-Reyes, Laura J","Sethna, Christine B","32447505"],"abstract":["COVID-19 is the illness caused by infection with the novel coronavirus SARS-CoV-2. Although myalgia is common in adults, it has not been noted as a common symptom in children. There have been a few reported cases of COVID-19-associated rhabdomyolysis in adults. This case report describes a 16-year-old boy who presented with fever, myalgias, mild shortness of breath with exertion, and dark-colored urine. COVID-19 PCR was positive. His initial creatinine kinase (CK) level was 427,656 U/L. Serum creatinine was normal for age. He was treated with isotonic intravenous fluids containing sodium bicarbonate to maintain urine output of 100-200 mL/h and urine pH > 7.0. His serum creatinine remained normal throughout the hospital stay and he was discharged on hospital day 12 with a CK of 6526 U/L. To our knowledge, no pediatric cases of COVID-19-associated rhabdomyolysis have been previously reported. Adult cases of rhabdomyolysis have been reported and a few reports have noted patients with elevated CK levels without rhabdomyolysis. Given this pediatric case of COVID-19-associated rhabdomyolysis, pediatric clinicians should be aware of this complication and manage fluids appropriately in order to prevent acute kidney injury."],"journal":"Pediatr Nephrol","authors":["Gefen, Ashley M","Palumbo, Nancy","Nathan, Suresh K","Singer, Pamela S","Castellanos-Reyes, Laura J","Sethna, Christine B"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447505","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00467-020-04617-0","keywords":["children","coronavirus","creatine kinase","sars-cov-2"],"locations":["myalgia"],"topics":["Case Report"],"weight":1,"_version_":1667698385922031617,"score":123.22492},{"pmid":32479664,"title":"A Case Series of MGUS and COVID-19.","text":["A Case Series of MGUS and COVID-19.","Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre-malignant clonal plasma cell disorder, with 25 to 30% life-long risk of progression to multiple myeloma (MM).(1) It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis, and acquired angioedema.(2) Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS.(3,4).","Br J Haematol","Gonzalez-Lugo, Jesus D","Bachier-Rodriguez, Lizamarie","Goldfinger, Mendel","Shastri, Aditi","Sica, R Alejandro","Gritsman, Kira","Mehta, Vikas","Kabarriti, Rafi","Goel, Sanjay","Verma, Amit","Braunschweig, Ira","Kornblum, Noah","Mantzaris, Ioannis","32479664"],"abstract":["Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre-malignant clonal plasma cell disorder, with 25 to 30% life-long risk of progression to multiple myeloma (MM).(1) It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis, and acquired angioedema.(2) Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS.(3,4)."],"journal":"Br J Haematol","authors":["Gonzalez-Lugo, Jesus D","Bachier-Rodriguez, Lizamarie","Goldfinger, Mendel","Shastri, Aditi","Sica, R Alejandro","Gritsman, Kira","Mehta, Vikas","Kabarriti, Rafi","Goel, Sanjay","Verma, Amit","Braunschweig, Ira","Kornblum, Noah","Mantzaris, Ioannis"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479664","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjh.16906","topics":["Case Report"],"weight":1,"_version_":1668437835199283201,"score":122.72946}]}